TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 24475837

Group type: EXPERIMENTAL
Intervention: Myocardial T1 values in diastole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Myocardial T1 values in systole
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blood-normalized myocardial T1 values
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Correlation of blood T1 with segmental myocardial T1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Blood-normalized diastolic and systolic myocardial T1 values
Number of subjects: 40
Study: 24475922

Group type: EXPERIMENTAL
Intervention: Empagliflozin (25 mg once daily for 8 weeks)
Number of subjects: 40
Study: 24476740

Group type: EXPERIMENTAL
Intervention: Progenitor cell therapy (CD34+ selected cell suspension injected into the wound)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Sham side (no progenitor cell treatment)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Histologic analysis after progenitor cell treatment
Number of subjects: 3
Study: 24477040

Group type: EXPERIMENTAL
Intervention: WIC program feeding practices
Number of subjects: 4000

Group type: EXPERIMENTAL
Intervention: Quantitative 24-h recall of food intake for the infant
Number of subjects: 4000
Study: 24477042

Group type: EXPERIMENTAL
Intervention: GCKR rs780094 TT genotype
Number of subjects: 797

Group type: EXPERIMENTAL
Intervention: PNPLA3 rs738409 variant
Number of subjects: 797

Group type: COMPARATOR
Intervention: NCAN, LYPLAL1, PPP1R3B variants
Number of subjects: 797
Study: 24477328

Group type: EXPERIMENTAL
Intervention: Intravenous azithromycin (500 mg, once daily for 2-5 days) followed by oral azithromycin (500 mg, once daily for 7-10 days)
Number of subjects: 102
Study: 24477368

Group type: EXPERIMENTAL
Intervention: Endoscopic papillectomy
Number of subjects: 93
Study: 24477369

Group type: EXPERIMENTAL
Intervention: ScopeGuide (electromagnetic field exposure)
Number of subjects: 100
Study: 24477453

Group type: EXPERIMENTAL
Intervention: Sodium lactate therapy (3-h intravenous infusion aiming to increase systemic lactate to ca. 5 mmol/L)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Sodium lactate therapy
Number of subjects: 15
Study: 24477603

Group type: EXPERIMENTAL
Intervention: 15.5 mg/m2 ombrabulin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 25 mg/m2 ombrabulin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 35 mg/m2 ombrabulin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50 mg/m2 ombrabulin
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 15
Study: 24477837

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Medication
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Combination of Cognitive Behavioral Therapy and Medication
Number of subjects: 288

Group type: COMPARATOR
Intervention: Pill Placebo
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Acute Treatment Responders
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Acute Treatment Non-Responders
Number of subjects: 288
Study: 24478152

Group type: EXPERIMENTAL
Intervention: Intracardiac echocardiography (ICE)
Number of subjects: 1

Group type: COMPARATOR
Intervention: Conventional transesophageal echocardiography (TEE)
Number of subjects: 1
Study: 24480627

Group type: EXPERIMENTAL
Intervention: 25-hydroxyvitamin D <20 ng/ml
Number of subjects: 3002

Group type: EXPERIMENTAL
Intervention: parathyroid hormone ≥65 pg/ml
Number of subjects: 3002

Group type: COMPARATOR
Intervention: 25-hydroxyvitamin D ≥30 ng/ml
Number of subjects: 3002

Group type: COMPARATOR
Intervention: parathyroid hormone <33 pg/ml
Number of subjects: 3002
Study: 24480783

Group type: EXPERIMENTAL
Intervention: e-Counseling + Usual Care
Number of subjects: 278

Group type: COMPARATOR
Intervention: e-Info Control + Usual Care
Number of subjects: 278
Study: 24480824

Group type: EXPERIMENTAL
Intervention: Rituximab (375 mg/m² intravenously, one or two doses)
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 22
Study: 24480929

Group type: EXPERIMENTAL
Intervention: Indwelling pleural catheters (IPCs)
Number of subjects: 266
Study: 24480997

Group type: EXPERIMENTAL
Intervention: Noninvasive positive pressure ventilation (NIV)
Number of subjects: 548

Group type: COMPARATOR
Intervention: Invasive mechanical ventilation
Number of subjects: 548
Study: 24481647

Group type: EXPERIMENTAL
Intervention: Upregulation of miR-378
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-378 overexpression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: miR-378 silencing
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical specimens
Number of subjects: 0
Study: 24481953

Group type: EXPERIMENTAL
Intervention: Triple therapy (TT) of vitamin K antagonist (VKA), aspirin, and clopidogrel
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: Dual antiplatelet therapy
Number of subjects: 914

Group type: EXPERIMENTAL
Intervention: VKA plus clopidogrel
Number of subjects: 914
Study: 24482099

Group type: EXPERIMENTAL
Intervention: Subcutaneous pasireotide 600 μg bid for 15 days
Number of subjects: 7
Study: 24484064

Group type: EXPERIMENTAL
Intervention: Renal colic protocol CT with a mean dose-length product (DLP) of 746 mGy ⋅ cm (effective dose, 11.2 mSv)
Number of subjects: 49903

Group type: EXPERIMENTAL
Intervention: Renal colic protocol CT with reduced dose (DLP of 200 mGy ⋅ cm or lower)
Number of subjects: 49903

Group type: EXPERIMENTAL
Intervention: Renal colic protocol CT with DLP at 400 mGy ⋅ cm or less
Number of subjects: 49903
Study: 24484456

Group type: EXPERIMENTAL
Intervention: Moderate Involvement/Low Conflict
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: Low Involvement/Moderate Conflict
Number of subjects: 156

Group type: EXPERIMENTAL
Intervention: High Involvement/High Conflict
Number of subjects: 156
Study: 24484754

Group type: EXPERIMENTAL
Intervention: Arteriovenous shunt creation
Number of subjects: 24
Study: 24485635

Group type: EXPERIMENTAL
Intervention: Intraatrial fat measurement in patients at low AF risk (n=15)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intraatrial fat measurement in patients at moderate AF risk (n=40)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Intraatrial fat measurement in patients at high AF risk (n=23)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Log-transformed intraatrial fat predicting ARIC AF risk score
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Interatrial septum width in patients at low AF risk (n=15)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Interatrial septum width in patients at moderate AF risk (n=40)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Interatrial septum width in patients at high AF risk (n=23)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Adjusted interatrial septum width
Number of subjects: 90
Study: 24486266

Group type: EXPERIMENTAL
Intervention: FFR(CT) derived from coronary computed tomography angiography (CTA)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Coronary CTA
Number of subjects: 254

Group type: COMPARATOR
Intervention: Invasive coronary angiography (ICA)
Number of subjects: 254
Study: 24486275

Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 24486892

Group type: EXPERIMENTAL
Intervention: Deep repetitive transcranial magnetic stimulation (DTMS) - 20 Hz, 3000 pulses/session for four weeks
Number of subjects: 15
Study: 24487484

Group type: EXPERIMENTAL
Intervention: Adalimumab 24 mg/m² (maximum 20 mg/dose) every other week up to 120 weeks
Number of subjects: 32
Study: 24488022

Group type: EXPERIMENTAL
Intervention: (111)In-labelled exendin
Number of subjects: 10
Study: 24488560

Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin (2.5 mg/kg/day for 4 doses)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Rabbit anti-thymocyte globulin
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: T-cell expression profiling
Number of subjects: 27
Study: 24488568

Group type: EXPERIMENTAL
Intervention: Rituximab
Number of subjects: 0
Study: 24488798

Group type: EXPERIMENTAL
Intervention: Midostaurin (25 or 50 mg orally twice daily) + all-trans retinoic acid (ATRA) + CLAG chemotherapy
Number of subjects: 10
Study: 24489687

Group type: EXPERIMENTAL
Intervention: Keratoconus group (group 1)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy subjects with corneal astigmatism (group 2)
Number of subjects: 40
Study: 24490070

Group type: EXPERIMENTAL
Intervention: Second Generation Antipsychotics
Number of subjects: 171
Study: 24491033

Group type: EXPERIMENTAL
Intervention: Paliperidone extended-release (ER)
Number of subjects: 1812
Study: 24491312

Group type: EXPERIMENTAL
Intervention: Evidence of cockroaches in any room
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Multifamily vs single-family dwellings
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Home characteristics
Number of subjects: 100
Study: 24491362

Group type: EXPERIMENTAL
Intervention: Laparoscopic gastric bypass surgery
Number of subjects: 81

Group type: COMPARATOR
Intervention: Conventional care
Number of subjects: 81
Study: 24491372

Group type: EXPERIMENTAL
Intervention: Daily self-monitoring of peak cough expiratory flow, oxygen saturation, and respiratory discomfort
Number of subjects: 18
Study: 24492296

Group type: EXPERIMENTAL
Intervention: ARGX-110 (defucosylated IgG1 monoclonal antibody)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fucosylated version of ARGX-110
Number of subjects: 0
Study: 24493150

Group type: EXPERIMENTAL
Intervention: BMI
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: WC
Number of subjects: 382

Group type: EXPERIMENTAL
Intervention: W/Ht
Number of subjects: 382
Study: 24493157

Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg/day p.o.
Number of subjects: 17
Study: 24493215

Group type: EXPERIMENTAL
Intervention: LCP-Tacro once-daily
Number of subjects: 57

Group type: COMPARATOR
Intervention: Prograf twice-daily
Number of subjects: 57
Study: 24493287

Group type: EXPERIMENTAL
Intervention: Gene expression signature including IL8 and LAMC2
Number of subjects: 64

Group type: COMPARATOR
Intervention: IL8 protein measurement
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Genetic targeting of Cxcr2 receptor in murine model
Number of subjects: 64
Study: 24493333

Group type: EXPERIMENTAL
Intervention: LC-MS/MS method for determination of venlafaxine and O-desmethylvenlafaxine in dried blood spots
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal hematocrit concentrations (0.30-0.50) and normal spot volume (40-80 μL)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Punch position at the perimeter of the blood spot
Number of subjects: 0
Study: 24493717

Group type: EXPERIMENTAL
Intervention: Itraconazole 200 mg twice per day for 1 month (cohort A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Itraconazole 100 mg twice per day for an average of 2.3 months (cohort B)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Itraconazole
Number of subjects: 29

Group type: COMPARATOR
Intervention: Control (untreated patients and those previously treated with vismodegib)
Number of subjects: 29
Study: 24495202

Group type: EXPERIMENTAL
Intervention: Chronic moderate to severe periodontitis
Number of subjects: 44

Group type: COMPARATOR
Intervention: Gingivitis and incipient periodontitis
Number of subjects: 44
Study: 24495442

Group type: COMPARATOR
Intervention: Before HSCT
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: After HSCT
Number of subjects: 40
Study: 24495890

Group type: EXPERIMENTAL
Intervention: Common Mental Disorder Questionnaire (CMDQ) anxiety subscale
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Common Mental Disorder Questionnaire (CMDQ) depression subscale
Number of subjects: 149

Group type: COMPARATOR
Intervention: Hospital Anxiety and Depression Scale (HADS) anxiety subscale
Number of subjects: 149

Group type: COMPARATOR
Intervention: Hospital Anxiety and Depression Scale (HADS) depression subscale
Number of subjects: 149
Study: 24496231

Group type: EXPERIMENTAL
Intervention: Elevated urinary globotriaosylceramide (Gb3) levels in heart disease patients without GLA mutations
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: Elevated urinary globotriaosylceramide (Gb3) levels
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: Fabry disease patients (n=7)
Number of subjects: 1408

Group type: EXPERIMENTAL
Intervention: Sphingomyelin and Gb3 levels
Number of subjects: 1408
Study: 24496782

Group type: EXPERIMENTAL
Intervention: 8 hours preoperative fasting
Number of subjects: 100
Study: 24496920

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 60 mg/m(2) weekly + cetuximab 250 mg/m(2) weekly + IMRT (70 Gy)
Number of subjects: 25

Group type: COMPARATOR
Intervention: nab-paclitaxel 80 mg/m(2) weekly + cetuximab + IMRT
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: nab-paclitaxel 60 mg/m(2) weekly + cetuximab + IMRT
Number of subjects: 25
Study: 24497495

Group type: EXPERIMENTAL
Intervention: cANCA or pANCA positivity
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: PR3-ANCAs or MPO-ANCAs positivity
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: cANCA/pANCA and PR3-ANCAs/MPO-ANCAs positivity
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Rheumatoid factor (RF) positivity
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Antinuclear antibodies (ANAs) positivity
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Anticardiolipin antibodies (aCL) positivity
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Association of cANCA/pANCA positivity with age
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Association of cANCA/pANCA positivity with echocardiographic vegetations
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Association of cANCA/pANCA positivity with serum IgG levels
Number of subjects: 109
Study: 24497573

Group type: EXPERIMENTAL
Intervention: Leadless ultrasound-based technology for LV endocardial resynchronization
Number of subjects: 17
Study: 24498123

Group type: EXPERIMENTAL
Intervention: Automatic extraction of lung vessels from contrast-enhanced thoracic CT scans and calculation of tortuosity using distance metric.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Automatic extraction of lung vessels from contrast-enhanced thoracic CT scans and calculation of 3D fractal dimension.
Number of subjects: 24
Study: 24498318

Group type: EXPERIMENTAL
Intervention: OCR 500 mg×2 plus background methotrexate (OCR500+MTX)
Number of subjects: 2759

Group type: EXPERIMENTAL
Intervention: OCR 200 mg×2 or 400 mg×1 plus background methotrexate (OCR200+MTX)
Number of subjects: 2759

Group type: COMPARATOR
Intervention: Placebo plus background methotrexate (placebo+MTX)
Number of subjects: 2759
Study: 24499022

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (MedDiet)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control diet
Number of subjects: 26
Study: 24499098

Group type: EXPERIMENTAL
Intervention: Arterial stiffness assessment as cardio-ankle vascular index
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Endothelial function assessment as reactive hyperemia index
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: SCORE calculation for cardiovascular risk
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Dietary intake assessment
Number of subjects: 94
Study: 24499406

Group type: EXPERIMENTAL
Intervention: Covariate-adjusted logistic regression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Unadjusted logistic regression
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Responder analysis outcomes
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified Rankin Scale (mRS)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Trichotomized National Institute of Health Stroke Scale (NIHSS)
Number of subjects: 0
Study: 24499496

Group type: EXPERIMENTAL
Intervention: NRL001
Number of subjects: 4
Study: 24499517

Group type: EXPERIMENTAL
Intervention: Once-daily insulin detemir
Number of subjects: 17374
Study: 24500145

Group type: EXPERIMENTAL
Intervention: Elevated intact parathyroid hormone (PTH) (>62 pg/mL) with very low calcium intake (<60% of EAR) or insufficient 25-hydroxyvitamin D (<20 ng/mL)
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Very low calcium intake (<60% of EAR)
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Very low 25(OH)D (<12 ng/mL)
Number of subjects: 1116

Group type: EXPERIMENTAL
Intervention: Elevated PTH (>62 pg/mL)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Insufficient 25(OH)D or very low calcium intake without elevated PTH or with elevated PTH alone
Number of subjects: 1116
Study: 24500148

Group type: EXPERIMENTAL
Intervention: Cobalt supplement (1.0 mg Co/d) for 90 days
Number of subjects: 10
Study: 24500151

Group type: EXPERIMENTAL
Intervention: Equations developed using anthropometric and demographic variables for predicting 24EE.
Number of subjects: 481

Group type: EXPERIMENTAL
Intervention: Refined equations using energy expenditure values after 3 h and 7 h into the chamber study.
Number of subjects: 481
Study: 24500152

Group type: EXPERIMENTAL
Intervention: Lipid-based nutrient supplements (LNS) containing sodium selenite and antiretroviral drugs (ARV)
Number of subjects: 526

Group type: COMPARATOR
Intervention: Control group (no LNS or ARV)
Number of subjects: 526
Study: 24500155

Group type: EXPERIMENTAL
Intervention: Magnesium intake >422.5 mg Mg/d
Number of subjects: 73684

Group type: EXPERIMENTAL
Intervention: Magnesium intake quintiles 4 and 5
Number of subjects: 73684
Study: 24500940

Group type: EXPERIMENTAL
Intervention: 2 stable magnesium isotopes (∼23 mg of oral ²⁶Mg and ∼11 mg of i.v. ²⁵Mg) administered to cohort 1
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Means of the 0-24 h urine and 3-h serum MgA values
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Means of the 0-24 h urine and 5-h serum MgA values
Number of subjects: 25
Study: 24501009

Group type: EXPERIMENTAL
Intervention: Dacomitinib (PF-00299804) 45 mg once daily continuously in 21-day cycles
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Dacomitinib (PF-00299804)
Number of subjects: 66
Study: 24502477

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting balloon (DEB)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Conventional balloon angioplasty (BA)
Number of subjects: 44
Study: 24502488

Group type: EXPERIMENTAL
Intervention: Multilayer Flow Modulator (MFM)
Number of subjects: 23
Study: 24502534

Group type: EXPERIMENTAL
Intervention: Intraarticular Botulinum toxin type A (BoNT-A) injection (100 units)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Intraarticular hyaluronate injection plus rehabilitation exercise (30 minutes/day, 3 times/week for 4 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intraarticular hyaluronate injection plus rehabilitation exercise
Number of subjects: 75

Group type: COMPARATOR
Intervention: Intraarticular BoNT-A injection
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 75
Study: 24502608

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy (CRT) optimization with echocardiography as reference
Number of subjects: 8

Group type: COMPARATOR
Intervention: Shorter (<100 ms) or longer (>160 ms) AV settings
Number of subjects: 8

Group type: COMPARATOR
Intervention: Ventricular (VV) optimization
Number of subjects: 8
Study: 24502968

Group type: EXPERIMENTAL
Intervention: Cardiac resynchronization therapy with defibrillator (CRT-D)
Number of subjects: 751
Study: 24503265

Group type: EXPERIMENTAL
Intervention: Intravenous human recombinant interferon-beta-1a (FP-1201) at an optimal tolerated dose of 10 μg per day for 6 days
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Intravenous human recombinant interferon-beta-1a (FP-1201)
Number of subjects: 37
Study: 24504435

Group type: EXPERIMENTAL
Intervention: ≥ 3 h/week vigorous activity
Number of subjects: 71

Group type: COMPARATOR
Intervention: No vigorous activity
Number of subjects: 71
Study: 24504442

Group type: EXPERIMENTAL
Intervention: Pazopanib
Number of subjects: 344
Study: 24504509

Group type: EXPERIMENTAL
Intervention: Vaccine-induced IgG antibodies to V1V2 regions of HIV-1 subtypes A, B, C, D, or CRF01_AE.
Number of subjects: 286

Group type: COMPARATOR
Intervention: Placebo group (control).
Number of subjects: 286
Study: 24504737

Group type: EXPERIMENTAL
Intervention: Lipopolysaccharide (low-dose)
Number of subjects: 6
Study: 24506412

Group type: EXPERIMENTAL
Intervention: Montelukast monotherapy (10 mg, once daily) in leukotriene-sensitive group
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Montelukast monotherapy (10 mg, once daily) in leukotriene-insensitive group
Number of subjects: 45
Study: 24506509

Group type: EXPERIMENTAL
Intervention: GMFCS level II
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: GMFCS level III
Number of subjects: 222

Group type: EXPERIMENTAL
Intervention: GMFCS level IV
Number of subjects: 222

Group type: COMPARATOR
Intervention: Educational facilities
Number of subjects: 222
Study: 24507585

Group type: EXPERIMENTAL
Intervention: Intensive aerobic exercise and muscle endurance training (15 on the Borg RPE scale, 3 times/week for 8 weeks)
Number of subjects: 4
Study: 24507865

Group type: EXPERIMENTAL
Intervention: Patients with childhood craniopharyngioma and hypothalamic involvement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patients with childhood craniopharyngioma and hypothalamic involvement (high-grade hypothalamic involvement)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Patients with childhood craniopharyngioma
Number of subjects: 15
Study: 24508104

Group type: EXPERIMENTAL
Intervention: Targeted therapy based on genomic alterations identified through CGH array and Sanger sequencing.
Number of subjects: 423

Group type: EXPERIMENTAL
Intervention: Targeted therapy received by 43 assessable patients.
Number of subjects: 423

Group type: COMPARATOR
Intervention: Biopsy procedure.
Number of subjects: 423
Study: 24508444

Group type: EXPERIMENTAL
Intervention: Intratracheal transplantation of hUCB-derived MSCs (1 × 10(7) cells/kg for first 3 patients, 2 × 10(7) cells/kg for next 6 patients)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Historical case-matched comparison group
Number of subjects: 9
Study: 24508509

Group type: EXPERIMENTAL
Intervention: NAVA (Neurally Adjusted Ventilator Assist)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: PSV (Pressure-Support Ventilation)
Number of subjects: 10

Group type: COMPARATOR
Intervention: NAVA
Number of subjects: 10

Group type: COMPARATOR
Intervention: PSV
Number of subjects: 10
Study: 24508570

Group type: EXPERIMENTAL
Intervention: Permacol™ surgical implant
Number of subjects: 343
Study: 24509907

Group type: EXPERIMENTAL
Intervention: Home-based exercise program
Number of subjects: 110